AbCellera Biologics Aktie
WKN DE: A2QKXS / ISIN: CA00288U1066
04.01.2023 22:05:00
|
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
Source: AbCellera Biologics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005877/en/

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AbCellera Biologics Inc Registered Shsmehr Nachrichten
23.04.25 |
Erste Schätzungen: AbCellera Biologics präsentiert Quartalsergebnisse (finanzen.net) | |
26.02.25 |
Ausblick: AbCellera Biologics zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
12.02.25 |
Erste Schätzungen: AbCellera Biologics zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
03.11.24 |
Ausblick: AbCellera Biologics zieht Bilanz zum abgelaufenen Quartal (finanzen.net) |
Analysen zu AbCellera Biologics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
AbCellera Biologics Inc Registered Shs | 2,27 | 0,85% |
|